Directors of Redbrick Molecular Ltd named as winners in Forbes 30 Under 30, Europe
23-Jan-2018 – Sheffield, UK: Directors of Redbrick Molecular Ltd named as winners in Forbes 30 Under 30, Europe
Redbrick Molecular Ltd Directors, Andy Hogben and James Gibbons have been named in the 2018 Forbes 30 under 30 in Europe list.
The two were honoured among 30 game-changing European entrepreneurs in science after establishing Redbrick Molecular, a spin out from The Universities of Sheffield and Leeds. The company enables pharmaceutical companies to develop life-saving medicines whilst contributing to the financial future of chemistry research in the UK.
“We set up Redbrick Molecular to generate a commercial impact from chemistry developed at universities, but what’s unique is our commitment to use all profits to fund further academic research,” said Andy Hogben, Managing Director. “It’s really exciting to generate products from the innovative science undertaken by some of the best academics in UK chemistry and we’re looking forward to establishing links with other universities as we grow.”
The company, which started trading in 2017, uses intellectual property licensed from academia to develop and manufacture ‘building block’ chemicals that are vital in the drug discovery process. The company aims to always be at the forefront of organic chemistry by working very closely with partner universities and industry.
“We’re producing a catalogue of novel, valuable materials that will form the basis of new life-saving drugs,” said James Gibbons, Director. “This recognition from Forbes really highlights the entrepreneurial, innovative spirit of the company, something also seen in our academic and university partners. We hope that Redbrick’s unique business model may become a template for future successful industry-academic interactions.”
Redbrick Molecular secured start-up loans from the Universities of Sheffield and Leeds. Scaling the business is the next challenge, and the company is focusing on growing its chemical catalogues and customer base. The founders will continue to engage with scientific and industrial leaders who are enthused by the idea of accessing exciting chemical products whilst contributing to the future of chemistry research in the UK.
Information for editors
Redbrick Molecular ltd develops innovative synthetic methodologies originating from its partner universities to produce attractive and novel building block chemicals for pharmaceutical research and development.
The company has a unique commercial model in which it produces compound catalogues for industrial customers and uses all profits to support future UK academic chemistry research. The business operates as an independent and self-governing limited company, positioned perfectly at the interface between industrial customers and academia to enable commercial impact whilst facilitating new collaborations.
Redbrick Molecular Ltd is a company limited by guarantee and owned by its members, currently The Universities of Leeds and Sheffield. Membership is expected to expand to other UK Universities over the coming years. The company laboratory is located at The Dainton Building, Sheffield.